Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Elizabeth Budde, Marissa Del Real, John Baird, Lu Chen, Joo Song, Xiuli Wang, Swetha Thiruvengadam, Marie Hu, Alan Macias, Emanuela Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Stephen Forman, Larry Kwak

Blood (2025) 146 (Supplement 1): 268.

https://doi.org/10.1182/blood-2025-268

Published: 2025

Journal Articles

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

Blood (2025) 146 (Supplement 1): 443.

https://doi.org/10.1182/blood-2025-443

Published: 2025

Journal Articles

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

Ryan Urak, Alexandra Wolfarth, Donghoon Choi, Stephen Forman, Xiuli Wang

Blood (2025) 146 (Supplement 1): 5878.

https://doi.org/10.1182/blood-2025-5878

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Ibrahim Aldoss, Xiuli Wang, Lu Chen, Joo Song, Karamjeet Sandhu, Alan Macias, Neguine Sanani, Baishakhi Barva, Min Guan, Ruby Espinosa, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Guido Marcucci, Elizabeth Budde, Larry Kwak, Stephen Forman

Blood (2025) 146 (Supplement 1): 813.

https://doi.org/10.1182/blood-2025-813

Published: 2025

Journal Articles

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

Enrico Caserta, Vikram Adhikarla, Maxim Kuznetkov, Ruby Espinosa, Mariam Murtadha, James Sanchez, Scott Goldsmith, Amrita Krishnan, Russell Rockne, John Shively, Xiuli Wang, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 801.

https://doi.org/10.1182/blood-2025-801

Published: 2025

Journal Articles

Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma

Xiuli Wang, Huifei Zheng, Sindhu Saraswathy, Jemily Juan, Isaac Garcia, Mary Clark, Stephen Forman, Enrique Montero

Blood (2025) 146 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2025-4110

Published: 2025

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Blood (2024) 144 (Supplement 1): 966.

https://doi.org/10.1182/blood-2024-201784

Published: 2024

Journal Articles

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Sheng-Hsuan Chien, Xiuli Wang, Wen-Chun Chen, Chun-Yu Liu

Blood (2023) 142 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2023-173443

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Saghar Pahlavanneshan, Ryan Urak, Ryotaro Nakamura, John Zaia, John H. Baird, Mary C Clark, Stephen J. Forman, Xiuli Wang

Blood (2023) 142 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2023-173757

Published: 2023

Journal Articles

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Blood (2022) 140 (Supplement 1): 4615–4616.

https://doi.org/10.1182/blood-2022-163439

Published: 2022

Journal Articles

Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Ryan Urak, Stephen J Forman, Xiuli Wang

Blood (2022) 140 (Supplement 1): 10648–10649.

https://doi.org/10.1182/blood-2022-169583

Published: 2022

Journal Articles

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Vibhuti Vyas, Lawrence Stern, Laura Lim, Christian Huynh, Ryan Urak, John C Williams, Stephen J Forman, Christine E Brown, Xiuli Wang

Blood (2022) 140 (Supplement 1): 12704–12705.

https://doi.org/10.1182/blood-2022-169803

Published: 2022

Journal Articles

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Tanya Siddiqi, Xiuli Wang, M. Suzette Blanchard, Jamie Wagner, Vibhuti Vyas, Mary C. Clark, Sandra Thomas, Baishakhi Barva, Angelica Gamez, Leslie L. Popplewell, Alex F. Herrera, Elizabeth Budde, Liana Nikolaenko, Christine E Brown, Stephen J Forman

Blood (2021) 138 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2021-147082

Published: 2021

Journal Articles

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Blood (2021) 138 (Supplement 1): 387.

https://doi.org/10.1182/blood-2021-145664

Published: 2021

Journal Articles

Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor

Ryan Urak, Ashlie Munoz, Hui-Ju Hsieh, Ellie Taus, Stephen J Forman, Xiuli Wang

Blood (2021) 138 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2021-153507

Published: 2021

Journal Articles

Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity

Dennis Awuah, Lawrence Stern, Ian Schrack, Tae Yoon Kim, Joseph Cohen, Ryan Urak, Christian Huynh, Wen-Chung Chang, Stephen J Forman, Xiuli Wang

Blood (2021) 138 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2021-153927

Published: 2021

Journal Articles

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

Xiuli Wang, Zhenyuan Dong, Wen-Chung Chang, Wesley Cheng, Vibhuti Vyas, Dennis Awuah, Soung-chul Cha, Aaron Anderson, Mary C. Clark, Stephen J Forman, Larry W. Kwak, Hong Qin

Blood (2021) 138 (Supplement 1): 2783.

https://doi.org/10.1182/blood-2021-151293

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor

Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only